Should Low-intensity Extracorporeal Shockwave Therapy Be the First-line Erectile Dysfunction Treatment for Nonresponders to Phosphodiesterase Type 5 Inhibition?

Premal Patel; Mikkel Fode; Tom Lue; Ranjith Ramasamy

doi:10.1016/j.euf.2019.02.004

Should Low-intensity Extracorporeal Shockwave Therapy Be the First-line Erectile Dysfunction Treatment for Nonresponders to Phosphodiesterase Type 5 Inhibition?

Eur Urol Focus. 2019 Jul;5(4):526-528. doi: 10.1016/j.euf.2019.02.004. Epub 2019 Feb 15.

Authors

Premal Patel¹, Mikkel Fode², Tom Lue³, Ranjith Ramasamy⁴

Affiliations

¹ Department of Urology, University of Miami, Miami, FL, USA.
² Department of Urology, Herlev and Gentofte Hospital, Herlev, Denmark.
³ Department of Urology, University of California, San Francisco, San Francisco, CA, USA.
⁴ Department of Urology, University of Miami, Miami, FL, USA. Electronic address: ramasamy@miami.edu.

PMID: 30777724
DOI: 10.1016/j.euf.2019.02.004

Abstract

Some trials have shown an overall benefit of low-intensity extracorporeal shockwave therapy (LI-ESWT) for erectile dysfunction, while others have been unable to find differences between LI-ESWT and sham treatment. In the absence of definitive evidence, patients should only be offered LI-ESWT in an investigational setting or on an off-label basis with a thorough understanding of the risks and benefits.

MeSH terms

Erectile Dysfunction / drug therapy
Erectile Dysfunction / therapy*
Extracorporeal Shockwave Therapy* / methods
Humans
Male
Phosphodiesterase 5 Inhibitors / therapeutic use
Practice Guidelines as Topic
Treatment Failure

Substances

Phosphodiesterase 5 Inhibitors